{"title":"Advances in pyrimidine-like heterocyclic scaffolds: Innovative synthetic method for malic enzyme inhibition in pancreatic ductal adenocarcinoma (PDAC) - A comprehensive review","authors":"Shubham Mehta , Iti Patel , Gautam Patel","doi":"10.1016/j.ejmech.2026.118657","DOIUrl":"10.1016/j.ejmech.2026.118657","url":null,"abstract":"<div><div>Pancreatic cancer remains one of the most lethal cancers of the 21st century due to extensive metabolic reprogramming and a highly adaptable tumor microenvironment that fosters relentless growth and resistance to treatment. Molecular docking studies targeted on malic enzyme facilitate the discovery of possible inhibitors that interfere with pancreatic cancer metabolism. Understanding the molecular circuitry of this disease, especially through the use of heterocyclic frameworks that inhibit metabolic needs specific to cancer, has enabled targeted therapy. Pyrimidine and fused-pyrimidine structures have become unique scaffolds because they are very good at breaking down metabolic checkpoints that are important for tumors to stay alive. Pyrimidine derivatives are at the forefront of developing next-generation anticancer drugs because they inhibit the malic enzyme (ME), which is a key regulator of redox homeostasis and biosynthetic flux in pancreatic cancers. This review gives a full picture of the synthetic methods that make it easy to quickly change the structure of pyrimidine-based pharmacophores. Some of these strategies are old, like Vorbrüggen glycosylation and HATU-mediated peptide coupling. Others are new, like chalcone-guanidine cyclocondensation and modular multi-component protocols. Pyrimidine scaffolds are crucial elements of precision oncology, evidenced by data from preclinical and clinical studies that underscore the therapeutic translatability of targeting metabolic abnormalities in pancreatic cancer. Even though chemotherapy, targeted therapy, and immunotherapy have all become better in the last few years, treating pancreatic cancer is still challenging due to its late diagnosis, the drug resistance, and the fact that there aren't many suitable options for treatment. Apart from that, there are still some big problems to solve, like metabolic redundancy, isoform-selective ME inhibition, and the tumor microenvironment, which makes treatment harder. To overcome these challenges, the amalgamation of multi-pathway inhibition, AI-driven lead optimization, and nanotechnology-facilitated targeted delivery offers considerable promise. This review emphasizes the crucial function of pyrimidine scaffolds in revolutionizing the therapeutic strategy for pancreatic cancer, linking mechanistic understanding to practical drug discovery.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118657"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146135332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yujian Yang , Binhao Rong , Huanyu Shi , Kunyu Lu , Xinxin Lin , Yuanmei Wen , Xingyu Zhou , Peisen Zheng , Xinshan Deng , Xumu Zhang , Shuwen Liu , Qifan Zhou
{"title":"Rational design of dual PB2/JAK2 inhibitors achieving balanced antiviral and host-directed immunomodulatory effects","authors":"Yujian Yang , Binhao Rong , Huanyu Shi , Kunyu Lu , Xinxin Lin , Yuanmei Wen , Xingyu Zhou , Peisen Zheng , Xinshan Deng , Xumu Zhang , Shuwen Liu , Qifan Zhou","doi":"10.1016/j.ejmech.2026.118642","DOIUrl":"10.1016/j.ejmech.2026.118642","url":null,"abstract":"<div><div>Infection with the influenza virus provokes an excessive immune reaction, triggering a cytokine storm that can cause severe inflammation and lead to conditions such as pneumonia and myocarditis. Herein, we propose a dual-target strategy that simultaneously targets the viral PB2 protein and the host JAK2 kinase, aiming to not only eliminate the virus but also modulate the immune response, facilitating rapid recovery of the body's health. In this article, the design and discovery of novel PB2/JAK2 dual-target inhibitors are reported. Through rational design and structure-guided optimization, we identified compound <strong>4B</strong>, which exhibited potent anti-H1N1 activity (MDCK cell EC<sub>50</sub> = 15 nM) and JAK2 inhibitory activity (JAK2 IC<sub>50</sub> = 49 nM). <strong>Notably, 4B demonstrated favorable pharmacokinetic properties in mice, achieving excellent oral bioavailability (F = 99.4%).</strong> Furthermore, our findings show that compound <strong>4B</strong> significantly downregulates NP and PB2 protein expression. Concurrently, <strong>4B</strong> also inhibits the mRNA expression of key pro-inflammatory cytokines (IL-6, TNF-α, IFN-β) in both inflammatory and influenza-infected models. This study demonstrates the promising potential of dual inhibition, targeting both viral replication and the host inflammatory response, for the development of anti-influenza therapeutics.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118642"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146135341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhe Wang , Zhengtong Mao , Chunwei Shen , Renying Wang, Bin Liu, Xingxian Zhang
{"title":"Design and optimization of N-(3-((4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)amide derivatives as potent anti-inflammatory agents against LPS-induced acute lung injury","authors":"Zhe Wang , Zhengtong Mao , Chunwei Shen , Renying Wang, Bin Liu, Xingxian Zhang","doi":"10.1016/j.ejmech.2026.118639","DOIUrl":"10.1016/j.ejmech.2026.118639","url":null,"abstract":"<div><div>Efficient treatment of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) can be achieved by inhibiting the inflammatory cascade and reducing pulmonary inflammation. A series of novel <em>N</em>-(3-((4-(1<em>H</em>-indol-3-yl)pyrimidin-2-yl)amino)phenyl)amide derivatives were rationally designed and synthesized as cathepsin L (CTSL) inhibitors to reduce the expression of pro-inflammatory cytokines. Among these compounds, <strong>B5</strong> exhibited dose-dependent inhibition of pro-inflammatory cytokine production in HBE cells, with IC<sub>50</sub> values of 2.51 μM for IL-6 and 1.15 μM for IL-8, without inducing significant cytotoxicity <em>in vitro</em>. In addition, <strong>B5</strong> effectively inhibited CTSL enzymatic activity, with an IC<sub>50</sub> value of 5.52 μM. In LPS-induced ALI mouse model, treatment with <strong>B5</strong> (20 mg/kg) significantly reduced inflammatory cell infiltration into lung tissue, thereby markedly alleviating lung injury. Mechanistic studies revealed that <strong>B5</strong> suppresses CTSL maturation, which in turn attenuates activation of the downstream NF-κB and p38 MAPK signaling pathways. Molecular docking further demonstrated that <strong>B5</strong> establishes stable binding in the active site of CTSL through multiple noncovalent interactions with key residues Asp162, Cys25, and Glu63. Specifically, the NH linker, the pyrimidine ring, and the amino group participate in hydrogen bonding, π–sulfur interactions, and electrostatic interactions, respectively. These findings indicate that <strong>B5</strong> exhibits potent anti-inflammatory activity both <em>in vitro</em> and <em>in vivo</em> and represents a promising lead compound for the treatment of ALI.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118639"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ninan Dai , Yiyu Wang , Yong Yang , Yuting Zhang , Huan Ge , Farhad Ghazali , Bao Fu , Yinhu Wang , Song Qin
{"title":"Structural optimization of natural product honokiol to discover novel membrane-targeting antibacterial agents against Gram-positive bacteria","authors":"Ninan Dai , Yiyu Wang , Yong Yang , Yuting Zhang , Huan Ge , Farhad Ghazali , Bao Fu , Yinhu Wang , Song Qin","doi":"10.1016/j.ejmech.2026.118674","DOIUrl":"10.1016/j.ejmech.2026.118674","url":null,"abstract":"<div><div>The global increase in infections caused by multidrug-resistant bacteria, coupled with a dwindling antibiotic pipeline, underscores an urgent need for new therapeutic agents. Inspired by the design principles of cationic antimicrobial peptides, we developed a new class of honokiol-based amphiphiles. From this series, compound <strong>20C</strong> emerged as a promising lead, demonstrating potent <em>in vitro</em> activity against Gram-positive bacteria (MICs = 0.5-2 μg/mL). It exhibited a favorable safety profile characterized by low hemolytic (HC<sub>50</sub> = 771.8 μg/mL) and cytotoxic activity (CC<sub>50</sub> = 28.03 μg/mL), along with good plasma stability. <strong>20C</strong> also displayed rapid bactericidal kinetics, a low resistance frequency, and efficacy in inhibiting biofilm formation and disrupting mature biofilms. A detailed mechanistic investigation established that <strong>20C</strong> exerted its effect by dissipation of membrane potential, increasing permeability, thereby disrupting membrane integrity. This primary membrane damage triggered secondary lethal events, including ROS accumulation and leakage of proteins and DNA. Notably, <strong>20C</strong> displayed superior efficacy compared to vancomycin in an <em>in vivo</em> infection model. These findings established <strong>20C</strong> as a promising candidate and underscore the potential of this amphiphilic design strategy in antibiotic discovery.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118674"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146153255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hui Wan , Yihang Liu , Huimin Chang , Kai Zhang , Zhenzhen Li , Haisen Ni , Jie Xu , Bo Pan , Kongkai Zhu , Junchi Hu , Shuai Wang , Dongqin Yang , Xiaobo Wang , Yongjun Dang , Sanyong Zhu
{"title":"Development of the first-in-class RNF4 PROTAC degrader as potential therapeutics for hepatocellular carcinoma","authors":"Hui Wan , Yihang Liu , Huimin Chang , Kai Zhang , Zhenzhen Li , Haisen Ni , Jie Xu , Bo Pan , Kongkai Zhu , Junchi Hu , Shuai Wang , Dongqin Yang , Xiaobo Wang , Yongjun Dang , Sanyong Zhu","doi":"10.1016/j.ejmech.2026.118668","DOIUrl":"10.1016/j.ejmech.2026.118668","url":null,"abstract":"<div><div>Ring Finger Protein 4 (RNF4) recognizes poly-SUMOylated proteins via its SUMO-Interacting Motifs (SIMs) and subsequently ubiquitinates them, thus effecting some key regulatory proteins involved in cancer development and progression. Our previous study found RNF4 was a potential target for HCC interruption. However, none of its inhibitor has been developed so far. Targeting RNF4 for degradation, rather than mere binding, emerged as a promising alternative strategy. To this end, we designed, synthesized and evaluated 28 PROTACs targeting RNF4 based on a reported covalent binder. Among them, <strong>RD12</strong> was identified as the lead compound through a systematic screening. <strong>RD12</strong> showed efficient RNF4 degradation activity as well as potent anti-proliferative activity in multiple HCC cell lines. Notably, it exhibited significant anti-tumour activity in a HCC mouse model without noticeable side effects. Mechanistic studies confirmed <strong>RD12</strong> degraded RNF4 via the ubiquitin-proteasome system, and it induced DNA damage and apoptosis. These findings collectively underscore <strong>RD12</strong> as the first pioneering RNF4 degrader and indicate its potential for HCC therapy.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118668"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146153097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Discovery of novel structural imidazolylvinylquinolones exerting excellent broad-spectrum antibacterial efficacy with multitargeting potential","authors":"Yi-Min Tan , Aisha Bibi , Jin-Ping Chen , Wei-Wei Gao , Yu Cheng , Cheng-He Zhou","doi":"10.1016/j.ejmech.2026.118643","DOIUrl":"10.1016/j.ejmech.2026.118643","url":null,"abstract":"<div><div>A unique type of imidazolylvinylquinolones (IVQs) as novel structural scaffold were developed which afforded excellent broad-spectrum antibacterial efficacy with multitargeting potential. Most of the prepared IVQs gave high antibacterial activity and broad antibacterial spectrum, and especially ethyl IVQ <strong>14a</strong>, in which the ethyl group was the most suitable fragment among all the investigated substituents to perform the most effective biosupramolecular effect, showed potent antibacterial activity against MRSA (MIC = 0.25 μg/mL), with an enhanced efficacy 16-fold that of ciprofloxacin. Molecule <strong>14a</strong> also demonstrated low drug resistance, hemolysis, and cytotoxicity, and rapidly bactericidal ability. Mechanism evaluation revealed that molecule <strong>14a</strong> could not only interfere with membranous function and form DNA-<strong>14a</strong> supramolecular complex by intercalation that might obstruct DNA replication, but also effectively interact with lactate dehydrogenase <em>via</em> hydrogen bonds which could obstruct the function of enzyme and inhibit bacterial metabolism, thereby exerting potent bactericidal effect. These potential multitargeting antibacterial actions enabled ethyl IVQ <strong>14a</strong> to exhibit stronger anti-MRSA efficacy without the obvious development of bacterial resistance than ciprofloxacin <em>in vivo</em>. This series of medicinal chemobiological evaluation towards the topic compounds strongly suggested the development potential of unique imidazolylvinylquinolones as novel structural scaffold to combat bacterial resistance.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118643"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyerin Yim , Xiangyang Song , Yue Zhong, Jacqueline Hu, Yan Xiong, Jian Jin
{"title":"Discovery of KRAS-G12D degraders via exploration of various E3 ligases","authors":"Hyerin Yim , Xiangyang Song , Yue Zhong, Jacqueline Hu, Yan Xiong, Jian Jin","doi":"10.1016/j.ejmech.2026.118635","DOIUrl":"10.1016/j.ejmech.2026.118635","url":null,"abstract":"<div><div>PROteolysis TArgeting Chimera (PROTAC) is a promising modality for targeted protein degradation. Although 600+ E3 ligases exist in the human genome, most PROTACs exploit a very limited set of E3 ligases, primarily CRBN and VHL. In this study, we designed, synthesized and evaluated a series of KRAS-G12D degraders that recruit one of four E3 ligases (CRBN, VHL, DCAF1, or KLHDC2) using a common KRAS-G12D binder derived from the KRAS-G12D inhibitor MRTX1133. Through this structure–activity relationship (SAR) study, we discovered two potent degraders: <strong>30</strong> (CRBN-based) and <strong>41</strong> (VHL-based), both of which effectively degraded KRAS-G12D and suppressed downstream signaling. By introducing a triazole-based VHL ligand, we subsequently discovered <strong>43</strong>, which showed improved degradation and antiproliferative activity comparable to a previously reported KRAS-G12D degrader. In contrast, KLHDC2- and DCAF1-based degraders failed to induce KRAS-G12D degradation, potentially due to suboptimal ternary complex formation or insufficient E3 ligase compatibility. These findings highlight the importance of E3 ligase selection in the development of effective KRAS-G12D degraders.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118635"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aylin Berwanger , Konrad Wagner , Simon Both , Andreas M. Kany , Kyana Mazlom , Anna K.H. Hirsch , Alexandra K. Kiemer , Martin Empting
{"title":"Identification of a new protein-RNA interaction inhibitor targeting the KH34 region of the insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2/IMP2)","authors":"Aylin Berwanger , Konrad Wagner , Simon Both , Andreas M. Kany , Kyana Mazlom , Anna K.H. Hirsch , Alexandra K. Kiemer , Martin Empting","doi":"10.1016/j.ejmech.2026.118624","DOIUrl":"10.1016/j.ejmech.2026.118624","url":null,"abstract":"<div><div>Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2/IMP2) plays a crucial role in the posttranscriptional regulation of gene expression and influences various cellular processes including cell growth, differentiation, and metabolism. Dysregulation of IMP2 has been associated with several diseases, including cancer and metabolic disorders. Targeting IMP2 with small molecules is a promising therapeutic strategy. However, the structural diversity of IMP2-targeting compounds remains limited. In this study, we present a comprehensive screening approach with the aim of identifying new structural classes of compounds that can inhibit IMP2 activity, particularly its binding to the KH34 domain. Screening of a chemically diverse library comprising 10,240 compounds using fluorescence polarization–based assays led to the identification of ten primary actives belonging to five distinct structural classes. After rigorous resynthesis and hit validation, only one compound comprising a sulfonamide scaffold reproducibly inhibited the KH34–RNA interaction <em>in vitro</em>. This hit was further characterized by STD-NMR and <em>in vitro</em> ADME profiling, including solubility, lipophilicity, metabolic stability, plasma protein binding, and cellular permeability. While this sulfonamide-based inhibitor exhibits clear biochemical activity and a defined binding mode at the KH34 RNA-binding interface, its limited cellular permeability and high plasma protein binding currently preclude cellular efficacy. This work identifies a new structural class of IMP2 KH34 inhibitors serving as a starting point for an ongoing hit-to-lead optimization campaign towards next-generation anti-cancer drugs.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118624"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146135335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carl P. Soltau , Ban Qi Tay , Alexander P. Martyn , Derek J. Richard , Mark N. Adams , Steven E. Bottle
{"title":"Structure-activity relationship of steroidal-nitroxide hybrids: Dual-modulators of glucocorticoid receptor signalling and cellular redox state","authors":"Carl P. Soltau , Ban Qi Tay , Alexander P. Martyn , Derek J. Richard , Mark N. Adams , Steven E. Bottle","doi":"10.1016/j.ejmech.2026.118655","DOIUrl":"10.1016/j.ejmech.2026.118655","url":null,"abstract":"<div><div>Inflammation and redox imbalance are hallmarks of many diseases. Here, we report the synthesis and systematic evaluation of steroid-nitroxide hybrid compounds as dual-acting anti-inflammatory and redox-modulating agents. Hybrids were generated <em>via</em> ester (<strong>1a-c</strong>, <strong>2a-b</strong>), amide (<strong>1d-h</strong>), and ether (<strong>3a-c</strong>) linkages at the C21 position of corticosteroids prednisolone, cortisol, and dexamethasone. The hybrids exhibit glucocorticoid receptor (GR) activity and suppress IL-6 secretion <em>in vitro</em> at variable potencies, some comparable to commercial corticosteroids. Cellular metabolic evaluation demonstrates various rates of intracellular cleavage for ester- and amide-linked hybrids, while ether-linked hybrids remain intact. Assessment of general reactive oxygen species (ROS) levels <em>via</em> the fluorogenic probe 2′,7′-dichlorofluorescein diacetate (DCFDA) demonstrated linker-dependent pro-oxidative effects, with poorly labile and non-cleavable compounds (<strong>1a</strong>, <strong>3a-c</strong>) causing sustained ROS elevation, while cleavable hybrids produced only transient, recoverable increases. Notably, one hybrid (<strong>1a</strong>) demonstrated higher ROS elevation in A549 cells over normal human fibroblasts (i.e. NFF cells) suggesting certain structural features of this hybrid induce specificity. Live-cell imaging using fluorescent analogues supports the mechanism of intracellular cleavage and efflux for cleavable hybrids, while non-cleavable hybrids remain within the cell. These findings demonstrate that steroidal-nitroxide hybrids harness both anti-inflammatory and redox modulation pathways, positioning them as a novel treatment strategy where dual anti-inflammatory and pro-oxidant strategies are advantageous.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118655"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146138918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Su Yu , Shichuan Hu , Weilin Wang , Chuntao Pan , Hongjia Zhang , Cong Zhou , Yang Liu , Rui Li
{"title":"Semi-rigid linkers improve the pharmacokinetic properties and therapeutic efficacy of BET PROTACs for cancer therapy","authors":"Su Yu , Shichuan Hu , Weilin Wang , Chuntao Pan , Hongjia Zhang , Cong Zhou , Yang Liu , Rui Li","doi":"10.1016/j.ejmech.2026.118644","DOIUrl":"10.1016/j.ejmech.2026.118644","url":null,"abstract":"<div><div>PROTACs offer a novel therapeutic strategy for addressing diseases driven by aberrant expression of pathogenic proteins. In this study, we identified a series of PROTAC molecules capable of degrading BRD2, BRD3, and BRD4. Structure–activity relationship analysis led to the discovery of <strong>CR10</strong>, a highly potent degrader that exhibited remarkable activity in MV4-11 cells. Mechanistic studies demonstrated that <strong>CR10</strong> induced sustained degradation of target proteins <em>via</em> the ubiquitin–proteasome system. In mice models, intraperitoneal administration at 20 mg/kg achieved an exceptional bioavailability of 108.27%. Furthermore, <strong>CR10</strong> significantly inhibited the growth of MV4-11 and A549 xenograft tumors at a dose as low as 2 mg/kg, without apparent toxicity. This semi-rigid linker–containing degrader represented a promising new mechanism-based candidate for the treatment of hematologic malignancies and lung cancer, warranting further investigation.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118644"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}